Canada Med Stop
FDA issued a warning letter to Canada Med Stop, a Vancouver-based online pharmacy, after reviewing its website in August 2025 and finding false or misleading claims about compounded semaglutide products offered to U.S. consumers. The site claimed its products contained the 'same active ingredient in branded weight loss medications,' were 'FDA-Approved,' and were 'GENERIC' — all of which are false or misleading because compounded drugs are not FDA-approved. FDA found the products misbranded under FDCA sections 502(a) and 502(bb), and warned that failure to correct violations may result in seizure or injunction.
Flagged claims (3)
The same active ingredient in branded weight loss medications.
FDA-Approved Medication
GENERIC
Required actions (3)
You should take immediate action to address any violations (including, for example, ceasing and desisting from using the language cited above that misbrands the product).
Within fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)'s Office of Compliance describing the specific steps you have taken to address any violations.
Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.
Does your site contain similar claims?
The free site audit scans your whole site against every entry in this Atlas. Most pharmacy / compounding sites match 3-6 patterns.
Run my free site auditWorried about one specific page, ad, or email? Paste it into the free Claim Checker and see what the FDA and FTC would flag, with the precedent next to each one. No email required.
Check specific copy in the Claim Checker